"We are excited to provide an updated assessment of objective response to dordaviprone previously reported in the blinded independent central review (BICR) cohort 1 in recurrent H3 K27M-mutant diffuse ...
“We are excited to provide an updated assessment of objective response to dordaviprone previously reported in the blinded independent central review (BICR) cohort 1 in recurrent H3 K27M-mutant diffuse ...
Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...
Edward White has given his Buy rating due to a combination of factors related to Chimerix’s promising developments in their treatment for H3 K27M-mutant diffuse glioma. The updated Phase 2 data for ...
Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...